Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
L Xiong, Y Lou, H Bai, R Li, J Xia… - Journal of …, 2020 - journals.sagepub.com
Background The optimal neoadjuvant regimen for locally advanced resectable non-small
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
[HTML][HTML] Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
L Xiong, Y Lou, H Bai, R Li, J Xia, W Fang… - The Journal of …, 2020 - ncbi.nlm.nih.gov
Background The optimal neoadjuvant regimen for locally advanced resectable non-small
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
L Xiong, Y Lou, H Bai, R Li, J Xia… - The Journal of …, 2020 - pubmed.ncbi.nlm.nih.gov
Background The optimal neoadjuvant regimen for locally advanced resectable non-small
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.
L Xiong, Y Lou, H Bai, R Li, J Xia, W Fang… - The Journal of …, 2019 - europepmc.org
Background The optimal neoadjuvant regimen for locally advanced resectable non-small
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
[PDF][PDF] Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
L Xiong, Y Lou, H Bai, R Li, J Xia, W Fang… - Journal of … - pdfs.semanticscholar.org
Background: The optimal neoadjuvant regimen for locally advanced resectable non-small
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …
Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
L Xiong, Y Lou, H Bai, R Li, J Xia, W Fang… - Journal of International …, 2019 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background</jats: title>< jats: p> The optimal neoadjuvant
regimen for locally advanced resectable non-small cell lung cancer (NSCLC) remains …
regimen for locally advanced resectable non-small cell lung cancer (NSCLC) remains …